iovera

Executive Summary

iovera is a medical device company specializing in targeted, drug-free pain relief through its proprietary cryoneurolysis technology. The FDA-cleared iovera° system delivers precise, extreme cold to temporarily block peripheral nerves, providing immediate and long-lasting pain relief for conditions such as osteoarthritis and postoperative recovery. Founded in 2004 and headquartered in Redwood City, California, the company addresses a significant unmet need in pain management, offering a non-opioid alternative that can reduce reliance on pharmaceuticals. With an aging population and increasing focus on non-addictive pain therapies, iovera is well-positioned to capitalize on trends favoring minimally invasive, drug-free interventions. Despite its established technology and FDA clearance, iovera faces competition from other neuromodulation and cryotherapy devices, as well as conservative reimbursement landscapes. The company is privately held, with limited public financial disclosures, but its longevity suggests steady revenue generation. Key growth drivers include expanding indications beyond osteoarthritis and postsurgical pain, forging strategic partnerships with orthopedic or sports medicine practices, and accumulating real-world evidence to support broader adoption. If the company can navigate regulatory expansions and scale its commercial presence, iovera could capture a meaningful share of the multi-billion-dollar pain management market.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for new indication (e.g., chronic low back pain)65% success
• Q4 2026Strategic partnership with major orthopedic device company50% success
• Q2 2026Publication of pivotal real-world evidence study in peer-reviewed journal70% success